MX2023004658A - Proceso para la preparacion de derivados de 6-(4-nitro-fenoxi)-2h- piridazin-3 -ona y 6-(4-amino-fenoxi)-2h-piridazin-3-ona como intermedios de analogos de hormona tiroidea. - Google Patents

Proceso para la preparacion de derivados de 6-(4-nitro-fenoxi)-2h- piridazin-3 -ona y 6-(4-amino-fenoxi)-2h-piridazin-3-ona como intermedios de analogos de hormona tiroidea.

Info

Publication number
MX2023004658A
MX2023004658A MX2023004658A MX2023004658A MX2023004658A MX 2023004658 A MX2023004658 A MX 2023004658A MX 2023004658 A MX2023004658 A MX 2023004658A MX 2023004658 A MX2023004658 A MX 2023004658A MX 2023004658 A MX2023004658 A MX 2023004658A
Authority
MX
Mexico
Prior art keywords
pyridazin
phenoxy
derivatives
intermediates
nitro
Prior art date
Application number
MX2023004658A
Other languages
English (en)
Inventor
Pasquale N Confalone
A Samuel Vellekoop
Original Assignee
Madrigal Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madrigal Pharmaceuticals Inc filed Critical Madrigal Pharmaceuticals Inc
Publication of MX2023004658A publication Critical patent/MX2023004658A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La descripción describe un método para preparar derivados de piridazinona que comprende poner en contacto un compuesto de la Fórmula (I) o una sal del mismo: (I) con un compuesto de la Fórmula (II) o una sal del mismo: (II) para formar un compuesto de la Fórmula (III) o una sal del mismo: (III). Después se puede convertir un compuesto de la Fórmula (III) en un compuesto de la Fórmula (IV):(IV), que se puede usar para preparar compuestos para tratar una enfermedad o trastorno hepático, o una enfermedad o trastorno lipídico.
MX2023004658A 2020-10-23 2021-10-20 Proceso para la preparacion de derivados de 6-(4-nitro-fenoxi)-2h- piridazin-3 -ona y 6-(4-amino-fenoxi)-2h-piridazin-3-ona como intermedios de analogos de hormona tiroidea. MX2023004658A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063104898P 2020-10-23 2020-10-23
US202163150616P 2021-02-18 2021-02-18
PCT/US2021/055865 WO2022087141A1 (en) 2020-10-23 2021-10-20 Process for the preparation of 6-(4-nitro-phenoxy)-2h-pyridazin-3-one and 6-(4-amino-phenoxy)-2h-pyridazin-3-one derivatives as intermediates of thyroid hormone analogues

Publications (1)

Publication Number Publication Date
MX2023004658A true MX2023004658A (es) 2023-05-18

Family

ID=78617529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004658A MX2023004658A (es) 2020-10-23 2021-10-20 Proceso para la preparacion de derivados de 6-(4-nitro-fenoxi)-2h- piridazin-3 -ona y 6-(4-amino-fenoxi)-2h-piridazin-3-ona como intermedios de analogos de hormona tiroidea.

Country Status (11)

Country Link
US (1) US20240051925A1 (es)
EP (1) EP4232436A1 (es)
JP (1) JP2023547381A (es)
KR (1) KR20230117564A (es)
CN (1) CN116406356A (es)
AU (1) AU2021366655A1 (es)
CA (1) CA3195960A1 (es)
IL (1) IL301821A (es)
MX (1) MX2023004658A (es)
TW (1) TW202233583A (es)
WO (1) WO2022087141A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024141104A1 (zh) * 2022-12-31 2024-07-04 南京知和医药科技有限公司 一种新型哒嗪类化合物及其药物组合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2543813T3 (es) * 2004-11-02 2015-08-24 Northwestern University Compuestos de piridazina para el tratamiento de enfermedades inflamatorias
AU2019287679B2 (en) 2018-06-12 2022-04-21 Xizang Haisco Pharmaceutical Co., Ltd. Thyroid hormone receptor agonists and uses thereof
WO2020073974A1 (en) * 2018-10-12 2020-04-16 Inventisbio Shanghai Ltd. Thyroid hormone receptor agonists
CN111320609A (zh) * 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途

Also Published As

Publication number Publication date
AU2021366655A1 (en) 2023-05-18
KR20230117564A (ko) 2023-08-08
CN116406356A (zh) 2023-07-07
JP2023547381A (ja) 2023-11-10
US20240051925A1 (en) 2024-02-15
WO2022087141A1 (en) 2022-04-28
AU2021366655A9 (en) 2024-09-26
TW202233583A (zh) 2022-09-01
CA3195960A1 (en) 2022-04-28
EP4232436A1 (en) 2023-08-30
IL301821A (en) 2023-06-01

Similar Documents

Publication Publication Date Title
MY147440A (en) Process for making 3-substituted 2-amino-5-halobenzamides
MX2021012669A (es) Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5- il)-piridin-3-il)metoxi)benzaldehido.
PL1789432T3 (pl) Sole metanosulfonianowe 3-estrów abirateronu i odzyskiwanie soli 3-estrów abirateronu z roztworu w eterze metylowo-tert-butylowym
MX2023004658A (es) Proceso para la preparacion de derivados de 6-(4-nitro-fenoxi)-2h- piridazin-3 -ona y 6-(4-amino-fenoxi)-2h-piridazin-3-ona como intermedios de analogos de hormona tiroidea.
NZ777524A (en) Fxr (nr1h4) modulating compounds
BRPI0612475B8 (pt) métodos para a preparação de um composto
BR112012015748A2 (pt) método para preparar uma composição antitranspirante líquida anidra
JOP20170172A1 (ar) أملاح إضافة حمض من مشتق بنز ايميدازول ((s)-4-(5، 7-داي فلورو كرومان-4-يل أوكسي)-N، N، 2- تراي ميثيل -1H-بنزو[d]ايميدازول-6-كربوكساميد)
MY167899A (en) Process for the preparation of methionine
CA2796744A1 (en) Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
EA201990237A1 (ru) Новые способы получения стимуляторов растворимой гуанилатциклазы
WO2014078669A4 (en) Carboxylic acid ester prodrug inhibitors of mek
UA93860C2 (ru) Способ получения пиразолов, способ региоселективного алкилирования и применение фосфата или фосфоната b способе
JOP20180126A1 (ar) عمليات جديدة من أجل تحضير منشطات محلقة غوانيلات قابلة للذوبان
MX354498B (es) Cristal de hidrato 5-hidroxi-1h-imidazol-4-carboxamida-3/4, metodo para producir el mismo y cristal de hidrato de 5-hidroxi-1h-imidazol-4-carboxamida.
MX2021001116A (es) Metodos para purificar sulfato de isavuconazonio.
MY149706A (en) Method for producing aqueous ?-sulfo fatty acid alkyl ester salt solution
RU2014142545A (ru) Способ получения 5-(дифторметил)пиразин-2-карбоновой кислоты и промежуточного соединения при ее получении
MX2023000382A (es) Inmunomoduladores heterocíclicos.
ATE533758T1 (de) Verfahren zur herstellung von enantiomerenreinem esomeprazol
BR112022003622A2 (pt) Processo para a síntese do sal de sódio do ácido 4-[[(1r)-2-[5-(2-flúor-3-metoxifenil)-3-[[2-flúor-6-(trifluormetil)-fenil]metil]-3,6-diidro-4-metil-2,6-dioxo-1(2h)-pirimidinila]-1-feniletil]amino]-butanóico (sal de sódio de elagolix) e intermediários do referido processo
WO2012015255A3 (en) Novel montelukast 4-halobenzylamine salt and method for preparing montelukast sodium salt by using the same
MX2021006692A (es) Proceso mejorado para preparar ozanimod.
BR112022001999A2 (pt) Processo melhorado para preparação de metil (2e)-2-(2-{[6-(2-cianofenoxi)pirimidin-4-il]oxi}fenil)-3-metoxiacrilato
MX2023001275A (es) Inhibidores de raf biciclicos fusionados y metodos para su uso.